Welcome to our dedicated page for Medipharm Labs news (Ticker: MEDIF), a resource for investors and traders seeking the latest updates and insights on Medipharm Labs stock.
MediPharm Labs Corp (MEDIF) is a leader in pharmaceutical-grade cannabis extraction and precision cannabinoid manufacturing, serving global medical markets through GMP-certified facilities. This page aggregates official news and verified updates about the company’s strategic initiatives, regulatory compliance milestones, and international expansion efforts.
Investors and industry professionals will find timely reports on earnings, partnership announcements, product innovations, and quality control advancements. Our curated collection simplifies tracking MEDIF’s progress in developing non-combustible delivery systems and expanding into regulated markets like Germany and Australia.
All content is sourced from company releases and accredited financial publications to ensure accuracy. Bookmark this page for streamlined access to MEDIF’s latest developments in pharmaceutical cannabis manufacturing, B2B white-label services, and API production.
Apollo Capital, owning 3% of MediPharm Labs (OTCQB: MEDIF), has issued a stark warning about the company's financial deterioration following Q1 2025 results. The company reported a $3.3 million loss in Q1, with only $8.4 million remaining in cash. At the current burn rate, MediPharm risks insolvency by November 2025.
The company faces severe revenue decline across all segments: international sales dropped 18%, Canadian medical cannabis revenue fell 6%, and adult-use revenue declined 23%. After 21 consecutive quarters of losses, Apollo Capital is urging shareholders to support board-level changes by electing their six nominees to reverse the company's decline and prevent potential bankruptcy.
Apollo Technology Capital Corporation, owning approximately 3% of MediPharm Labs, has posed critical questions for MediPharm's management ahead of their first conference call since Q2 2024. The call comes after MediPharm's stock lost 99% of its value, representing nearly $1 billion in shareholder losses. Apollo Capital views the sudden conference call as a reaction to their announcement to nominate six directors at the upcoming June 16, 2025 Annual Meeting.
Apollo Capital has nominated experienced candidates including John Fowler, Alan D. Lewis, David Lontini, Demetrios Mallios, Regan McGee, and Scott Walters to bring turnaround, M&A, and operational expertise to MediPharm's board. The activist investor criticizes current management for poor performance, questionable accounting practices, excessive compensation, and lack of transparency.
MediPharm Labs (MEDIF), a pharmaceutical company focused on precision-based cannabinoids, has scheduled the release of its first quarter 2025 financial results for Wednesday, May 14, 2025, before markets open. The company will host a conference call and webcast on the same day at 10:00 a.m. Eastern time to discuss the financial results.
Investors can join via North America Toll-Free at (888) 330-2454 or International Toll at +1 (240) 789-2714 using Conference ID 4921762. A webcast replay will be available on the company's investor relations website approximately one day after the call.
Apollo Technology Capital Corporation, owning approximately 3% of MediPharm Labs, has announced plans to nominate six directors to MediPharm's Board at the upcoming June 10, 2025 Annual Meeting. This move comes after MediPharm's stock price plummeted by over 99% from CAD $7.39 to CAD $0.06 between May 2019 and December 2024, resulting in nearly $1 billion in lost market capitalization.
Apollo criticizes the current board, led by Chairman Chris Taves, for failed operational strategies, excessive compensation, and $54 million in operating losses over the last three years. The nominees include industry veterans John Fowler, Alan D. Lewis, David Lontini, Demetrios Mallios, Regan McGee, and Scott Walters, who bring experience in turnaround operations, M&A, and cannabis industry expertise.
MediPharm Labs (MEDIF) reported strong financial results for FY2024, with annual net revenue increasing 27% to $42M, driven by record $18M international medical cannabis revenue. The company achieved significant profitability improvements, with gross profit reaching $12.8M (31% margin) compared to $5.8M (18%) in 2023.
Q4 2024 showed remarkable progress with revenue of $12M, up 32% year-over-year, and gross profit of $3.6M (30% margin). International revenue represented 54% of Q4 revenue, growing from $2.4M to $6.5M. The company maintained a strong balance sheet with $11.7M in cash and is materially debt-free after repaying $2M of convertible debt.
The company announced the planned sale of its Hope facility for $4.5M, with expected closure in Q2, while operations were consolidated to the Barrie facility, resulting in $1M annual savings.
MediPharm Labs (TSX: LABS) (OTCQB: MEDIF) has announced it will release its full year and fourth quarter 2024 financial results on Monday, March 31st, 2025, before markets open. The pharmaceutical company, which specializes in precision-based cannabinoids, will make available an updated company presentation including select highlights from the period ended December 31st, 2024 on their website following the earnings release. The company has noted that this presentation will replace a quarterly earnings call with management.
MediPharm Labs (TSX: LABS, OTCQX: MEDIF) has announced the termination of the previously planned sale of its Napanee Facility to Kensana Health. The termination occurred because Kensana Health failed to meet certain agreed-upon terms and conditions within specified timelines. Under the Purchase Agreement terms, MediPharm will retain certain non-refundable deposits from Kensana Health.
The company confirms that current commercial agreements and operations at the Napanee Facility will continue without disruption. MediPharm reports increasing demand for their international B2B GMP services at both Barrie and Napanee facilities, citing profitable international revenue growth in 2024. The company plans to continue utilizing the Napanee Facility to pursue international opportunities in 2025.
MediPharm Labs (TSX: LABS, OTCQX: MEDIF) has provided an update on the previously announced sale of its Napanee Facility in Ontario. The company has agreed with Kensana Health to extend the closing date of the transaction to January 31, 2025. The deal involves selling MediPharm's indirect equity interests in its wholly-owned subsidiary ABcann Medicinals to Kensana Health for $5.5 million in cash. The transaction remains subject to customary closing conditions and necessary approvals. Operations at the Napanee Facility continue without disruption during this period.
MediPharm Labs (TSX: LABS, OTCQX: MEDIF) has secured a commercial agreement with Laboratório Teuto, a major Brazilian pharmaceutical manufacturer. ANVISA granted Teuto Sanitary Authorizations for two MediPharm-manufactured products on December 30, 2024, with initial shipments expected to begin after receiving import and export permits.
The Brazilian medical cannabis market, estimated to be worth $198 million in 2024 with over 670,000 patients, is growing at over 20% annually and projected to exceed $260 million by 2026. Teuto, with 77 years of industry experience, operates a 140,000-square-meter facility producing over 500 pharmaceutical products annually.
MediPharm is among few North American companies with multiple ANVISA sanitary authorizations and an ANVISA GMP license. Currently, only 36 valid cannabis product authorizations exist under RDC 327/2019 in Brazil's strictly regulated market.
FAQ
What is the current stock price of Medipharm Labs (MEDIF)?
What is the market cap of Medipharm Labs (MEDIF)?
